Home/AtriCure/Angela L. Wirick
AL

Angela L. Wirick

Chief Financial Officer

AtriCure

AtriCure Pipeline

DrugIndicationPhase
BoxX-NoAF Clinical TrialPrevention of new-onset post-operative atrial fibrillationPivotal Trial
Hybrid AF Therapy (EPi-Sense)Symptomatic Persistent & Long-Standing Persistent Atrial FibrillationCommercial
Cryo Nerve Block ExpansionPain management for new surgical indications (e.g., abdominal, orthopedic)R&D